Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)
Status:
Withdrawn
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to determine the safety, tolerability and preliminary
efficacy of alemtuzumab for infusion for the treatment of CIDP. Eligible subjects will be
treated with alemtuzumab at the beginning of the study and then followed for three years.
During the three year period, subjects will under go monthly safety evaluations consisting of
blood and urine testing, symptom surveys and examination. Detailed neurological testing
including nerve conduction testing, Rasch-built Overall Disability Scale (CIDP/RODS) and
Overall Neuropathy Limitations Scale (ONLS) assessments will be performed every six months
for three years.
The study will also investigate and compare the responsiveness of the outcome measures being
used.